Orchid Pharma Ltd

BSE: 524372

36

total announcements

524372.BO · 15 min delayed

BSECompany UpdateResults2d ago

Orchid Pharma Ltd

Board Comments on fine levied by Stock Exchanges

Orchid Pharma Ltd has been fined Rs. 2000 each by National Stock Exchange of India Limited and BSE Limited for a one-day delay in filing its annual report. The company's board has taken note of the payment of fines and advised the management to strengthen its internal compliance monitoring mechanism.

Read more →📎 1 attachment
BSECompany Update▲ PositiveResults2d ago

Orchid Pharma Ltd

Investor Presentation-Quarter II of FY 2026-27, ended on September 30, 2026

Orchid Pharma Ltd has released its Investor Presentation for Q2 FY 2026-27, showcasing its financial performance and business prospects. The company has made significant progress in its anti-infectives business, with a strong presence in regulated markets and a focus on long-term growth.

Read more →📎 1 attachment
BSECompany UpdateResults4d ago

Orchid Pharma Ltd

Statement of deviation or variation for the quarter ended on September 30, 2026 on the use of proceeds of funds raised through Qualified institutional placement (QIP)

Orchid Pharma Ltd has filed a statement of deviation or variation for the quarter ended September 30, 2026, on the use of proceeds of funds raised through Qualified Institutional Placement (QIP). The company has reallocated the QIP proceeds from the API Facility in Alathur to other projects, citing changes in the business environment and strategic requirements.

Read more →📎 1 attachment
BSEResult▼ NegativeResults4d ago

Orchid Pharma Ltd

Declaration of Financial results for quarter and half year ended on September 30, 2026

Orchid Pharma Ltd has declared its unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2026. The company's net sales income for the quarter stood at ₹34,126.66 lakhs, a decrease of 14.5% from the same period last year. The company's profit before tax for the quarter was ₹2,683.69 lakhs, a decrease of 27.5% from the same period last year.

Read more →📎 1 attachment
BSEBoard MeetingResults4d ago

Orchid Pharma Ltd

Outcome of Board Meeting

Orchid Pharma Ltd's board meeting outcome announced unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2026. The company reported a net sales income of ₹34,126.66 crore and ₹64,543.79 crore for the quarter and half year respectively. Profit before tax stood at ₹3,675.93 crore and ₹4,869.65 crore for the quarter and half year respectively.

Read more →📎 1 attachment
BSEBoard MeetingResults11 Nov 2026

Orchid Pharma Ltd

Orchid Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/11/2026 ,inter alia, to consider and approve Unaudited Limited Reviewed Financial Results (Standalone & Consolidated) of the Company for the Quarter-II and half year ended on September 30, 2026.

Orchid Pharma Ltd has informed BSE that the meeting of the Board of Directors is scheduled on November 14, 2026, to consider and approve Unaudited Limited Reviewed Financial Results for the Quarter-II and half year ended on September 30, 2026.

Read more →📎 1 attachment
BSECompany UpdateFundraise20 Oct 2026

Orchid Pharma Ltd

Outcome of Board Meeting for Raising Funds ("Enabling Resolution")

Orchid Pharma Ltd's board has approved a proposal to raise up to Rs. 600 Crores through the issue of equity shares or other eligible securities, including convertible debentures, through various modes such as QIP, private placement, or public issue.

Read more →📎 1 attachment
BSEBoard Meeting▲ PositiveFundraise20 Oct 2026

Orchid Pharma Ltd

Outcome of Board Meeting

Orchid Pharma Ltd's board meeting outcome reveals the company's intention to explore potential market opportunities for raising funds through the issue of equity shares or other eligible securities, up to Rs. 600 Crores.

Read more →📎 1 attachment
BSEBoard MeetingFundraise15 Oct 2026

Orchid Pharma Ltd

Orchid Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 20/10/2026 ,inter alia, to consider and approve Prior intimation of Board Meeting scheduled to be held on October 20, 2026, inter alia to consider and approve enabling resolution for raising of funds

Orchid Pharma Ltd has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 20/10/2026 to consider and approve enabling resolution for raising of funds.

Read more →📎 1 attachment
BSECompany UpdateRegulatory9 Oct 2026

Orchid Pharma Ltd

Certificate under Regulation 74(5) of Securities and Exchange Board of India (Depositories and Participants) Regulation, 2018

Orchid Pharma Ltd has issued a certificate under Regulation 74(5) of the Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018, confirming the compliances required under the above said regulation for the Quarter-II of Financial Year 2026-27 ended on September 30, 2026.

Read more →📎 1 attachment
BSEAGM/EGM29 Sept 2026

Orchid Pharma Ltd

Proceedings of 33rd Annual General Meeting of Orchid Pharma Limited Held on 29th September 2026

Orchid Pharma Ltd held its 33rd Annual General Meeting on September 29, 2026, through video conferencing, with 32 members present. The meeting was chaired by Manish Dhanuka, Managing Director, after Ram Gopal Agarwal's absence. The company secretary informed the members about the auditors' report, which did not contain any qualification, but had certain qualifications in the consolidated auditor's report.

Read more →📎 1 attachment
Page 1 of 2Next →